Targeted drug activation to improve cancer treatment
Official title: Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry
Funded at Shasqi, INC. · NIH-11012264 · Data updated 2026-11-12
This study is testing a new way to deliver medicine that targets the disease directly, which could help you feel better while causing fewer side effects.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Shasqi, INC. NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,217,955 |
| NIH project number | 5R44CA285160-02 |
| Project ID | NIH-11012264 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with specific types of cancer who are seeking more effective treatment options with fewer adverse effects.
✕Less likely to help
Patients with conditions that do not involve localized drug activation or those who are not undergoing cancer treatment may not benefit from this research.
What this research studies
This research focuses on a novel platform that activates drugs directly at the site of disease, enhancing their effectiveness while reducing harmful side effects. By using a method called click chemistry, the approach allows for a protodrug to be administered throughout the body, which is then activated at the specific pathological site by an activating agent. This targeted delivery aims to minimize systemic toxicity and adverse drug events, which are common with traditional drug administration methods. Patients may experience improved treatment outcomes with fewer side effects as a result of this innovative approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with significantly reduced side effects.
How similar studies have gone: Similar approaches in targeted drug delivery have shown promise in previous studies, indicating potential for success in this novel application.
Where this research is happening
-
Shasqi, INC.
San Francisco, United States Active
Researchers
- Principal investigator: Mejia Oneto, Jose M — Shasqi, INC.
- Study coordinator: Mejia Oneto, Jose M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.